Championing cardiovascular health innovation in Europe

European Heart Journal

Volumn 34, Issue 33, 2013, Pages 2630-2635

  Komajda, Michel ^a   Coats, Andrew ^b   Cowie, Martin R ^c   Jackson, Neville ^d   Svensson, Anders ^e   Vardas, Panagiotis ^a  

^a European Society of Cardiology   (France)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d PFIZER INC   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; DRUG INDUSTRY; EUROPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PROMOTION; HUMAN; INVESTMENT; LIFESTYLE; MEDICAL EDUCATION; METABOLIC DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; DIFFUSION OF INNOVATION; DRUG INDUSTRY; EFFICIENCY, ORGANIZATIONAL; EUROPE; HEALTH EDUCATION; HEALTH EXPENDITURES; HEALTH PROMOTION; HUMANS; RESEARCH SUPPORT AS TOPIC; RISK FACTORS;

EID: 84883746530     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht211     Document Type: Review

References (24)

1. Cardiovascular Round Table. An Introduction to the CRT. http://www.esc-crt.org/about/Pages/about.aspx
2. EFPIA. The Pharmaceutical Industry in Figures, 2011 Update. http://www.efpia.eu/sites/www.efpia.eu/files/EFPIA-Figures-2012-Final-20120622- 003-EN-v1.pdf
3. Puska P, Nissinen A, Tuomilehto J, Salonen JT, Koskela K, McAlister A, Kottke TE, Maccoby N, Farquhar JW. The community-based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia Project. Annu Rev Public Health 1985;6:147-193.
4. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Scarborough P, Rayner M. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
5. Sipido K. Identifying needs and opportunities for advancing translational research in cardiovascular disease. Cardiovasc Res 2009;83:425-435.
6. Lenfant C. Clinical research to clinical practice-lost in translation? N Engl J Med 2003;349:868-874.
7. European Commission White Paper on A Strategy for Europe on Nutrition. Overweight and obesity related health issues. http://ec.europa.eu/health/ archive/ph-determinants/life-style/nutrition/documents/nutrition-wp-en.pdf
8. Federation of European Nurses in Diabetes and International Diabetes Federation. The policy puzzle. Is Europe making progress? Http://ec.europa.eu/ health/major-chronic-diseases/docs/policy-puzzle-2011.pdf
9. Roger VL, Go AS, Lloyd-Jones DM. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123: e18-e209.
10. Anand S, Yusuf S. Stemming the global tsunami of cardiovascular disease. Lancet 2011;377:529-532.
11. International Association for the Study of Obesity. Overweight and obesity in the EU27. http://www.iaso.org/site-media/uploads/v2PDFforwebsiteEU27. pdf
12. World Economic Forumand theHarvard School of PublicHealth. The global economic burden of non-communicable diseases. September 2011. http://www3.weforum. org/docs/WEF-Harvard-HE- GlobalEconomicBurdenNonCommunicableDiseases- 2011.pdf
13. Heidenreich PA. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123:933-944.
14. Thomson Reuters. The changing role of chemistry in drug discovery. http://thomsonreuters.com/content/science/pdf/ls/iyc2011.pdf
15. SCRIP Intelligence report. Kill, kill, kill! The worrying mortality of pharma pipelines. http://www.scripintelligence.com/home/Kill-kill-kill-The- worrying-mortality-ofpharma-pipelines-335166
16. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceuticalR and D. Nat Revi Drug Discov 2011;10:428-438.
17. US Pharmaceutical Industry Report, 2008-2009. http://www.pr-inside.com/ uspharmaceutical-industry-report-r1291427.htm
18. Laslett LJ. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues. J Am Coll Cardiol 2012;60:S1-S49.
19. EFPIA.Lifecycle of a new medicine. http://www.efpia.eu/Content/Default .asp?PageID=361EFPIA
20. The Economist. The future of healthcare in Europe. Economist Intelligence Unit Report, 2011. See table page 42.
21. The Telegraph. Witty lays out Glaxo vision with UK in lead. Feb 2013. http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/ 9859739/Wittylays-out-Glaxo-vision-with-UK-in-lead.html
22. MroczkowskiT. TheNewPlayers in Life Science Innovation. 1st ed.NewJersey: FT Press; 2011. p25.
23. MroczkowskiT. TheNewPlayers in Life Science Innovation. 1st ed.NewJersey: FT Press; 2011. p165.
24. European Medicines Agency. Monthly Statistics Report, September 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Report/2011/10/WC500116972. Pdf